Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Total Valuation
Cue Biopharma has a market cap or net worth of $25.96M. The enterprise value is -$1.98M.
Market Cap$25.96M
Enterprise Value-$1.98M
Share Statistics
Cue Biopharma has 97,660,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,660,790
Owned by Insiders0.57%
Owned by Institutions16.80%
Financial Efficiency
Cue Biopharma’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -86.69%.
Return on Equity (ROE)-1.01
Return on Assets (ROA)-0.63
Return on Invested Capital (ROIC)-86.69%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee669.90K
Profits Per Employee-648.83K
Employee Count41
Asset Turnover0.65
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cue Biopharma is ―. Cue Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio1.05
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-1.32
Price to Operating Cash Flow-1.32
PEG Ratio0.02
Income Statement
In the last 12 months, Cue Biopharma had revenue of 27.47M and earned -26.60M in profits. Earnings per share was -0.28.
Revenue27.47M
Gross Profit23.99M
Operating Income-26.55M
Pretax Income-26.10M
Net Income-26.60M
EBITDA-23.04M
Earnings Per Share (EPS)-0.28
Cash Flow
In the last 12 months, operating cash flow was -21.69M and capital expenditures -177.00K, giving a free cash flow of -21.86M billion.
Operating Cash Flow-21.69M
Free Cash Flow-21.86M
Free Cash Flow per Share-0.22
Dividends & Yields
Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change-74.27%
50-Day Moving Average0.31
200-Day Moving Average0.59
Relative Strength Index (RSI)39.33
Average Volume (3m)238.59K
Important Dates
Cue Biopharma upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Cue Biopharma as a current ratio of 2.74, with Debt / Equity ratio of 15.88%
Current Ratio2.74
Quick Ratio2.74
Debt to Market Cap0.15
Net Debt to EBITDA1.00
Interest Coverage Ratio-74.38
Taxes
In the past 12 months, Cue Biopharma has paid 500.00K in taxes.
Income Tax500.00K
Effective Tax Rate-0.02
Enterprise Valuation
Cue Biopharma EV to EBITDA ratio is -0.26, with an EV/FCF ratio of -0.27.
EV to Sales0.22
EV to EBITDA-0.26
EV to Free Cash Flow-0.27
EV to Operating Cash Flow-0.28
Balance Sheet
Cue Biopharma has $27.14M in cash and marketable securities with $4.20M in debt, giving a net cash position of $22.94M billion.
Cash & Marketable Securities$27.14M
Total Debt$4.20M
Net Cash$22.94M
Net Cash Per Share$0.23
Tangible Book Value Per Share$0.28
Margins
Gross margin is 88.04%, with operating margin of -96.67%, and net profit margin of -96.85%.
Gross Margin88.04%
Operating Margin-96.67%
Pretax Margin-95.03%
Net Profit Margin-96.85%
EBITDA Margin-83.89%
EBIT Margin-96.56%
Analyst Forecast
The average price target for Cue Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-25.51%
EPS Growth Forecast49.72%